Pharmacology/Pharmaceutical Industry
Video: Frequently Asked COVID-19 Vaccine Questions – August 2021 Update.
12 Aug, 2021 | 08:59h | UTCFrequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA
Vaccination: Effectiveness versus Efficacy.
12 Aug, 2021 | 09:01h | UTCVaccination: Effectiveness versus Efficacy – by Luis Correa, MD
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
12 Aug, 2021 | 09:05h | UTCCommentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD
Related:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce
— NEJM (@NEJM) August 11, 2021
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.
12 Aug, 2021 | 08:51h | UTC
PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.
11 Aug, 2021 | 08:52h | UTCInvited Commentary: The use of inhaled corticosteroids in early-stage COVID-19
CDC Report: COVID-19 morbidity and mortality far exceed the potential risks of rare side effects caused by vaccines.
11 Aug, 2021 | 08:45h | UTC
Cluster RCT: Vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh conferred 85% total protection.
11 Aug, 2021 | 08:28h | UTCInvited commentary: Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever – The Lancet
Systematic review: Prescribing practices, patterns, and potential harms in patients receiving palliative care – “many patients receiving palliative care receive multiple medications closer to the time of death”.
11 Aug, 2021 | 08:23h | UTC
Commentary on Twitter
Useful overview of observational research about prescribing in #palliativecare – more work needed to assess appropriateness, potential harms and prescribing trendshttps://t.co/7abM5ANEH0
— deprescribing.org (@deprescribing) August 10, 2021
[Preprint] Phase 1/2 RCT: A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac.
10 Aug, 2021 | 09:58h | UTC
Commentary on Twitter
https://twitter.com/hildabast/status/1424644994120372224
A WHO expert explains why she believes the rush for Covid-19 boosters is premature.
10 Aug, 2021 | 09:56h | UTCA WHO expert explains why she believes the rush for Covid-19 boosters is premature – STAT
Commentary on Twitter
Must read interview on rich nations rushing into booster doses
Dr @Kate_L_OBrien by @HelenBranswell @statnews
"We really have huge inequity right now in just getting primary doses to people. Does a third dose need to be given?"https://t.co/pRhYwINuKf pic.twitter.com/YQS6Nj0Hyi
— Madhu Pai, MD, PhD (@paimadhu) August 9, 2021
‘Breakthrough’ infections do not mean COVID vaccines are failing.
10 Aug, 2021 | 09:54h | UTC‘Breakthrough’ Infections Do Not Mean COVID Vaccines Are Failing – Scientific American
Commentary on Twitter
https://twitter.com/laurahelmuth/status/1422897892797337609
Guideline: Endoscopy in patients on antiplatelet or anticoagulant therapy.
10 Aug, 2021 | 08:59h | UTC
Secondary analysis of RCT finds Dapagliflozin is safe for patients with stage 4 chronic kidney disease.
10 Aug, 2021 | 08:51h | UTCCommentaries:
No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD – HealthDay
Interactive infographic: Data shows how rare severe breakthrough Covid infections are.
9 Aug, 2021 | 00:01h | UTCData shows how rare severe breakthrough Covid infections are – NBC News
Commentary on Twitter
Very good interactive infographic for impact of vaccination in 2021 by state https://t.co/HAfYYPX9FI by @NBCNews @seenigel @ChicagoEl @pdrbarquinha @jiachuanwu @NBCNewsGraphics
Here for California: Hospitalizations, deaths and infections pic.twitter.com/83Hxl2x2gm— Eric Topol (@EricTopol) August 7, 2021
RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.
9 Aug, 2021 | 00:06h | UTCInvited commentary: Optimising SARS-CoV-2 vaccination schedules – The Lancet
Related: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter
Just published @TheLancet
A randomized mix and match trial of AZ and Pfizer vaccination in >800 people shows that mixing is safe and can engender at least as good, if not better, immune response https://t.co/V40Dy59Ia8 by @XinxueLiu and colleagues pic.twitter.com/tKl59LFz4i— Eric Topol (@EricTopol) August 6, 2021
COVID: WHO calls for moratorium on booster shots – is it justifiable?
8 Aug, 2021 | 23:54h | UTCCOVID: WHO calls for moratorium on booster shots – is it justifiable? – The Conversation
Related: Covid: WHO calls for booster pause to vaccinate poorer nations.
Commentary on Twitter
The authors put it well: Even if affluent countries prioritize boosters for the vulnerable, 'the degree of additional benefit…is uncertain.' Yet we know 'vaccines could do a huge amount of good for the large number of vulnerable ppl who've not yet received a single dose.' https://t.co/6qNV6pzDDk
— Tedros Adhanom Ghebreyesus (@DrTedros) August 7, 2021
CDC study showed a reduced risk of reinfection with SARS-CoV-2 after covid-19 vaccination.
9 Aug, 2021 | 00:03h | UTC
Commentaries on Twitter
This is non randomized. The two biases are:
1. Behavior among those who got vaccinated likely different than those who don't
2. Likely those who didn't tested more aggressively
I would not cite this as many are doinghttps://t.co/rSkBC37uq0
— Vinay Prasad MD MPH (@VPrasadMDMPH) August 7, 2021
Study shows that full #COVIDVaccination ⬇️ likelihood of being re-infected with #COVID19 compared to those who were previously had COVID but were not vaccinated (risk ⬆️ 2.3 fold)#GetVaccinated even if you have had COVID previouslyhttps://t.co/3dF3XPxwYp
@fascinatorfun pic.twitter.com/ip6zTvNN86
— Prof Kamlesh Khunti (@kamleshkhunti) August 7, 2021
COVID vaccine boosters: the most important questions.
8 Aug, 2021 | 23:52h | UTCCOVID vaccine boosters: the most important questions – Nature
Commentary on Twitter
I agree with @nataliexdean: “We just don’t have clear evidence of enough of a loss of efficacy to change our focus or distract from the main goal, which is trying to get as many people first doses” as possible." https://t.co/FEKB4vg0Dz
— Sanghyuk Shin (@sanghyuk_shin) August 6, 2021
More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID.
8 Aug, 2021 | 23:50h | UTCCommentary: One Dose of Pfizer Vaccine May Be Enough for Folks Who’ve Had COVID – HealthDay
Related:
Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.
Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Spain to give just one vaccine dose to under 55-year olds who had COVID-19
Perspective: Is one vaccine dose enough after COVID-19 infection?
France’s health authority recommends single vaccine shot for people who have had COVID-19
Covid-19: People who have had infection might only need one dose of mRNA vaccine
Commentary on Twitter
SARS-CoV-2 Antibody Responses After 1 and 2 Doses of the BNT162b2 Vaccine https://t.co/ARMdH8Yboo via @JAMANetworkOpen part of @JAMANetwork Small study but one that confirms the policy of many European countries in which one dose of vaccine is sufficient after having COVID.
— Carlos del Rio (@CarlosdelRio7) August 7, 2021
Case report: Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination.
8 Aug, 2021 | 23:49h | UTC
M-A: Colchicine in patients with coronary artery disease – “colchicine reduces the risk of myocardial infarction and stroke, but has a higher rate of gastrointestinal upset with no influence on all‐cause mortality”.
8 Aug, 2021 | 23:40h | UTCRelated:
Review: Colchicine and the heart.
M-A: Colchicine administration for percutaneous coronary intervention
M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease
Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease
Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease
#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome
Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome
Perspective | Expertise from outside the Academy: tapering off antidepressants.
8 Aug, 2021 | 23:27h | UTCExpertise from outside the Academy: tapering off antidepressants – The Mental Elf
Related:
A method for tapering antipsychotic treatment that may minimize the risk of relapse
Systematic Review: Managing Antidepressant Discontinuation
Randomized controlled trial: preventive cognitive therapy for prevention of depressive recurrence
Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.
6 Aug, 2021 | 10:15h | UTCRemdesivir for the treatment of COVID‐19 – Cochrane Library
Summary: Remdesivir for the treatment of COVID-19 – Cochrane Library
Commentary on Twitter (thread – click for more)
JUST PUBLISHED – Is #remdesivir an effective treatment for #COVID19? https://t.co/ntgfDQjMqs This @CochraneHaem systematic review looked at this antiviral medicine to see if it's an effective treatment for people in hospital w #COVID & if it causes unwanted effects. 1/5 pic.twitter.com/UtIW83uTtn
— The Cochrane Library (@CochraneLibrary) August 5, 2021
M-A: Pharmacotherapy for the prevention of chronic pain after surgery in adults.
6 Aug, 2021 | 09:51h | UTC
Commentary on Twitter
Pharmacotherapy for the Prevention of Chronic Pain after Surgery in Adults: An Updated Systematic Review and Meta-analysis https://t.co/DzILWovtGG #visualabstract pic.twitter.com/A8JIxKl942
— Anesthesiology (@_Anesthesiology) August 5, 2021
RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.
5 Aug, 2021 | 09:07h | UTCEditorial: Surviving Covid-19 with Heparin?
Commentaries:
Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD
Commentary on Twitter
In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. https://t.co/3JzKdmL3SB #IDTwitter pic.twitter.com/iDjSelp2HL
— NEJM (@NEJM) August 4, 2021